Latest Tax Rebates News

Page 8 of 10
Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.
Ada Torres
Ada Torres
29 Apr 2025
PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.
Ada Torres
Ada Torres
17 Feb 2025
Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.
Victor Sage
Victor Sage
7 Feb 2025
Spacetalk Ltd has secured a $428,853 R&D tax rebate from the Australian Taxation Office, reinforcing its commitment to innovation while reporting a 16% increase in Annual Recurring Revenue and significant cost reductions.
Sophie Babbage
Sophie Babbage
7 Feb 2025
Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.
Ada Torres
Ada Torres
3 Feb 2025
Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.
Ada Torres
Ada Torres
31 Jan 2025
Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.
Victor Sage
Victor Sage
31 Jan 2025
Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.
Ada Torres
Ada Torres
31 Jan 2025
Ionic Rare Earths reports strong progress on its Belfast rare earth oxide recycling facility, backed by a robust feasibility study and UK government grant applications, alongside strategic developments in Brazil and Uganda.
Maxwell Dee
Maxwell Dee
31 Jan 2025
Blue Energy Limited reports steady progress in its Sapphire Pilot gas production despite operational interruptions and ongoing environmental authority appeals, while advancing seismic exploration in the Northern Territory.
Maxwell Dee
Maxwell Dee
31 Jan 2025
dorsaVi reported a modest 1.9% rise in sales revenue to $330k in Q2 FY25, launched its AI-powered Video AI movement analysis platform, and initiated a blockchain integration partnership to enhance data security.
Victor Sage
Victor Sage
31 Jan 2025
BluGlass Limited has secured over A$4 million in new contracts and filed three US patents for high-power tunable GaN lasers, reinforcing its leadership in visible laser technology and expanding its footprint in strategic photonics markets.
Victor Sage
Victor Sage
31 Jan 2025